-
Article | 2021.10.18
Yersin Class (2014-2017)
Ph.D. StudentUndergraduate studiesLaboratoryThesis AdvisorLab HeadDoctoral SchoolPh.D. projectEugenia COVERNTONUniversidad Nacional de Rosario, ArgentinaStructural VirologyFrançois Bontems / Giovana Barba-SpaethFélix ReyMTCIStructure-function studies on yellow fever virusAnna FUNKThe London School of Hygiene and Tropical Medicine (LSHTM), UKEpidemiologyof Emerging ...
-
Document de presse | 2021.10.11
SARS-CoV-2 Alpha, Beta and Delta variants display enhanced viral fusion properties compared to ancestral strains
In a new study published in EMBO Journal on October 2, 2021, scientists from the Institut Pasteur, the CNRS, Université de Paris, the Vaccine Research Institute and Sorbonne University examined the fusion mechanisms of different SARS-CoV-2 variants: Alpha (initially identified in the United Kingdom), Beta (initially identified in South Africa) and Delta (initially identified in India). The Delta...
-
News | 2023.11.15
The Institut Pasteur pays tribute to Dr. Grancher, physician and “Pasteurian”
On November 7, 2023, the Grancher Foundation celebrated its 120th anniversary on the Institut Pasteur campus. The Foundation was established by Dr. Joseph Grancher. It was an opportunity for the Institut Pasteur's President to pay tribute to the physician best known for his work on tuberculosis – a disease that the Institut Pasteur continues to fight.
-
News | 2023.02.20
Two effective new antiviral drugs for SARS-CoV-2
Scientists at the Institut Pasteur have successfully synthesized two novel molecules that are active against several variants of the virus responsible for COVID-19. The discovery could inspire new families of antiviral drugs against future emerging viral diseases.
-
News | 2022.09.01
Malaria: blood stage of the parasite recreated in vivo to help tackle the disease
By engrafting human hematopoietic stem cells into mice, a team from the Institut Pasteur, Inserm and the CNRS was able to maintain the Plasmodium vivax parasite in vivo, providing a novel model to explore therapeutic strategies.
-
News | 2017.06.29
Viral hepatitis: the challenge of communication in Africa
WHO adopted in 2016 a global strategy to eliminate hepatitis B and C by 2030. On the basis of anthropological analyses conducted in multiple African countries, a group of researchers, including some from the Institut Pasteur, suggest that to achieve these goals it is essential to improve the communication about viral hepatitis. According to WHO, viral hepatitis caused 1.34 million deaths in...
-
Article | 2019.05.21
Emerging infectious diseases
Ever since its very early days, the Institut Pasteur has been committed to tackling emerging infections, and its work has left an extraordinary legacy. Many emerging infectious diseases are zoonoses, in which an animal pathogen has crossed the species barrier to cause disease in humans.
-
Document de presse | 2021.05.28
COVID-19: analysis of the sensitivity of the Delta variant to monoclonal antibodies and sera from convalescent and vaccinated individuals
The Delta variant was detected for the first time in India in October 2020 and has since spread throughout the world. It is now dominant in many countries and regions (India, the UK, Portugal, Russia, etc.) and is predicted to be the most prevalent variant in Europe within weeks or months. Epidemiological studies have shown that the Delta variant is more transmissible than other variants....
-
News | 2025.05.08
Avian influenza: a global epidemic under surveillance
Since 2022, the world has been grappling with a severe epizootic of avian influenza, affecting birds and sometimes also farmed mammals, primarily caused by the influenza A(H5N1) virus. Some sporadic cases have been observed in humans, but so far these have only been people who have come into close contact with infected animals. The H5N1 virus is circulating worldwide, except in Australia. And the...
-
Article | 2020.03.27
Coronavirus (Covid-19) research projects
VACCINE CANDIDATES1. Development of an animal model and accelerated development of a DNA vaccine candidate(SCARD SARS-CoV-2 project)Aims:To develop a mouse model of SARS-CoV-2 infection.This will not only enable us to evaluate the efficacy of the vaccine; it will also facilitate in vivo research on SARS-CoV-2. To evaluate the immunogenicity (ability to induce a specific immune reaction) and...